local_hospital

Helsinki University Central Hospital

Address
Haartmaninkatu 4, 00290 Helsinki, Finland

Cardiovascular Diseases

At Helsinki University Central Hospital the Heart and Lung Center concentrates on coronary artery disease, seeking to advance interventional care for patients with elevated bleeding risk.

  • Evaluation of drug‑coated balloon therapy
  • Comparison with drug‑eluting stents
  • Shortened dual‑antiplatelet therapy regimens
  • Strategies for high bleeding risk populations

Ongoing studies aim to demonstrate that a drug‑coated balloon approach combined with reduced dual‑antiplatelet therapy can be as effective as traditional drug‑eluting stents, offering safer options for those prone to bleeding.

Site Overview

lock Available with ACCESS

Activity Indicator

Last 6 months

lock Available with ACCESS

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 26 therapeutic areas and 15 of 511 IMPs, ranked by number of trials.

lock Available with ACCESS

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 470 compounds, ranked by number of trials.

lock Available with ACCESS

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
197
Sponsors (total)
129
Active sponsors
102

Sponsor Network

Top 102 by active trials.

lock +101 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +57 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 125 other sites in Finland

lock Available with ACCESS

Therapeutic Area Benchmark — Finland

Select a therapeutic area to compare against other sites in Finland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Finland

Market Share

Country: Finland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Helsinki University Central Hospital

lock Showing 1 of 332 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studiesBayer Consumer Care AGPhase IIINot RecruitingOct 2020—

IMP list

lock Showing 1 of 511 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cyclophosphamide22Unknown2015-05-052026-03-17

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.